Safety and Efficacy of Biphasic Remogliflozin Etabonate in the Treatment of Type 2 Diabetes
Phase 2
Completed
- Conditions
- Type 2 Diabetes MellitusDiabetes Mellitus, Type 2
- Interventions
- Other: PlaceboDrug: Biphasic Remogliflozin Etabonate
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2018-01-18
- Lead Sponsor
- BHV Pharma
- Target Recruit Count
- 191
- Registration Number
- NCT02537470
- Locations
- 🇺🇸
Advanced Arizona Clinical Research, Tucson, Arizona, United States
🇺🇸Chase Medical Research, Waterbury, Connecticut, United States
🇺🇸Long Beach Clinical Trials, Long Beach, California, United States
© Copyright 2025. All Rights Reserved by MedPath